Complement Mediated Glomerular Diseases

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Complement Mediated Glomerular Diseases trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT07522099

Chinese Adults With Kidney Disease

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases…

China30 participantsStarted 2026-07-23

Treatment: ADX-038, Telitacicept

All recent trials (12 shown)

CompletedPhase 1/2

NCT05083364

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patie…

Australia, Georgia, Germany62 participantsStarted 2022-02-01

Treatment: ARO-C3, Placebo

CompletedPhase 1

NCT06674915

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HRS-5965 in subjects with mild to moderate hepatic impairment and…

China24 participantsStarted 2024-11-26

Treatment: HRS-5965 capsules

Complement Mediated Glomerular Diseases

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Chinese Adults With Kidney Disease

All recent trials (12 shown)

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Chinese Adults With Kidney Disease

All recent trials (12 shown)

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

CHART-C3G/CLNP023B12011

Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects

A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers